



	Questions : Lok Sabha




























Screen Reader Access
Skip to Main Content
Skip to Navigation



Text Size

                                A

                                A
A















हिन्दी मे








Parliament of India Lok Sabha House of the
                        People






* Special Characters not allowed












India Time 


Your Time 


                        Tuesday,
                        12 April 2022









HomeMembersSitting MembersMembers Home PageMembers' PortalContact DetailsMembers SearchStatistical AnalysisAttendance of MembersHandbook Members Since 1952Digitized Who's WhoOthers BusinessProvisional CalendarList of BusinessPapers to be LaidList of Private Members' BusinessBulletin-IDigitized Lok Sabha Bulletin Part IBulletin-IIStatement of WorkSpecial Mentions (ZERO HOUR)Resume of WorkDigitized Resume of Work done by Lok Sabha QuestionsHomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions DebatesIntroductionSynopsisUncorrected DebateText of DebateDigitized DebatesConstituent Assembly DebatesWit And HumourDebate SearchHindi FontsDisclaimer Papers LaidPapers Laid on the Table of the House LegislationIntroduction(How Bill Becomes Act)Bills IntroducedBills PassedBills PendingBills AssentedBills LapsedBills WithdrawnBills NegativedBills Search Disclaimer CommitteesIntroductionChairpersonSummary of WorkCommittee Meetings ScheduleBills Referred to CommitteesReports PresentedDigitized ReportsPress ReleaseMembership SearchToday's Committee MeetingsCommittee Subject SelectedDepartment Related-RS Govt. AssurancesSANSAD TVIntranet





HomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions











Download as PDF




Print












PDF/WORD(Hindi)


PDF/WORD




                                    GOVERNMENT OF INDIA
                                





                                    MINISTRY OF
                                    AYURVEDA,YOGA & NATUROPATHY,UNANI,SIDDHA AND HOMEOPATHY (AYUSH)






                                    LOK SABHA
                                





UNSTARRED 


                                    QUESTION NO:
                                

3440






                                    ANSWERED ON: 
                                

17.12.2021






Technology of AYUSH-64




Suresh Kodikunnil













                                                    Bheemrao Baswanthrao Patil
                                                








                                                    Bhartruhari Mahtab
                                                












                        Will the Minister of





AYURVEDA,YOGA & NATUROPATHY,UNANI,SIDDHA AND HOMEOPATHY (AYUSH)


                        be pleased to state:-















                                                    (a)	whether the Central Council for Research in Ayurvedic Sciences (CCRAS) has transferred the technology of AYUSH-64, a drug used in mild and asymptomatic and mild to moderate cases of COVID-19, to different companies for manufacturing the medicine;(b)	if so, the details thereof, State/UT-wise;(c)	whether the Government proposes to promote usage of ayurvedic medications to treat patients experiencing COVID related medical conditions and post COVID ailments, if so, the details thereof;(d)	whether clinical trials of the said drug conducted by the Government and the Council of Scientific and Industrial Research (CSIR) has proved to be effective in treating COVID-19, if so, the details thereof;(e)	whether AYUSH-64 administered on patients quarantined at home was found beneficial, if so the details thereof; and(f)	whether the necessary guidelines laid down in Drugs and Cosmetics Act, 1940 were complied with in the case of the said drug, if so, the details thereof?






ANSWER




                                                        THE MINISTER OF AYUSH (SHRI SARBANANDA SONOWAL)(a)&(b)	Yes, Sir. The technology for manufacturing AYUSH 64 has been transferred to 46 companies. The details are annexed. (c)	Government of India has released “National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19” This protocol is for management of mild COVID-19. Moderate to Severe COVID-19 individuals may have informed choice of treatment options. It includes general &physical measures, dietary measures and symptom management for prophylactic care, asymptomatic COVID-19 positive and mild COVID-19 positive along with post-COVID management.In addition to this, Ministry of Ayush has also issued –i.	Guidelines for Registered Practitioners of respective system of AYUSH. These guidelines are made available in public domain for the benefit of registered AYUSH practitioners including Homoeopathy to help in the management of COVID 19 pandemic uniformly. ii.	Ayurveda, Unani and Siddha preventive measures for self-care during COVID-19 and Guidelines for Ayush Practitioners for COVID-19 Patients in Home Isolation.iii.	Home care guidelines for children and Advisory for AYUSH Practitioners about prophylactic care in Children during the COVID-19 Pandemic.iv.	Ayush Recommendations for the public on holistic health and well-being Preventive measures and care during COVID-19 and Long COVID-19. (d)&(e)	The Council of Scientific and Industrial Research (CSIR) and the Ministry of AYUSH has conducted clinical trials for AYUSH interventions for COVID-19, that included AYUSH-64. AYUSH-64 was found effective & safe, and recommended for mild to moderate COVID-19 patients. The outcome of the study has highlighted that AYUSH 64 has hastened clinical recovery, reduced hospitalization and improved overall health in mild and moderate COVID-19 when co-administered with standard of care. (f)	 All State Licensing Authorities (SLA''s)/Drug Controllers were requested to allow the licensed manufacturers for AYUSH-64 under their jurisdiction to include new indication of AYUSH 64 for repurposing as an intervention for the management of asymptomatic, mild to moderate COVID-19 in addition to existing indication(s) and also to expedite the process of the licensing/approval of such applications for the manufacturing of AYUSH 64 medicine, provided the prescribed standards and relevant provisions of the Drugs & Cosmetics Rules, 1945, are fulfilled.****
























HomeArchiveIndex to Select Questions (1984-1999)Ballot ListStatistical Statements Relating to QuestionsUploading of Questions - Status QueryProcedure for Sending Text of Questions & AnswersDemarcation of responsibilities in Govt. of IndiaBrochure on Statutory Corporations, Companies and Other Bodies in Which the Government of India have financial or controlling interestHighlights pertaining to questions of 17th Lok Sabha






Contact Us 
Disclaimer











        Developed and Hosted by National Informatics Centre (NIC)

Content on this website is published,
            managed & maintained by Software Unit, Computer (HW & SW) Management. Branch,
            Lok Sabha Secretariat





HomeMembersBusinessQuestionsDebatesPapers Laid


LegislationCommitteesSANSAD TVIntranetSecretariatPRIDE


RecruitmentSC/ST ReservationConferenceParliament Library


About ParliamentPhoto GalleryRelated LinksRTITendersFAQ


SpeakerDy. SpeakerLeader of the HousePanel of ChairpersonsContact UsFeedback


Council of MinistersPublications of MinistriesParliamentry ProceduresJournal of Parliamentary Information
Visitor's Counter:113249561







Copyright
Privacy Policy
Disclaimer
Terms &
                Conditions

                Accessibility Statement
Accessibility
                Options
Feedback
Site Map







